BrainStorm Cell Therapeutics to Meet with US FDA to Discuss Development Plan for NurOwn as a Treatment of ALS
Path forward for ALS is a registrational Phase 3b U.S. clinical trial
Biologics License Application to be withdrawn without prejudice
Conference call and webcast at 8:30am ET today
NEW YORK, Oct. 18, 2023 -- (Healthcare Sales & Marketing Network) ... Regenerative Medicine, Neurology BrainStorm Cell Therapeutics, NurOwn, stem cell
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Brain | Clinical Trials | Conferences | Marketing | Neurology | Pharmaceuticals | Stem Cell Therapy | Stem Cells